Navigation Links
NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Date:3/31/2008

HUBBARD, Ohio, March 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company is pleased to provide the following updates on company events:

NanoLogix personnel are manning a booth and presenting at the National Hydrogen Association Expo in Sacramento this week, with the company being represented by William Hartman and Chris Novak. Mr. Hartman will be presenting in the Exhibition Hall today, March 31, from 2:00-2:30 pm, on "Biohydrogen and Electricity Production from Waste Water".

Company CEO Bret Barnhizer was Marlene Bourne's guest on The Bourne Report March 16, on the topic of Hydrogen Power. The interview provides updates on hydrogen bioreactor operations. Access: http://www.bournereport.com/radio.php

Work on BNC and BNP development for fast microorganism detection is proceeding at a rapid pace, with a new patent application filed in March and positive developments with both the Departments of Defense and Homeland Security in late February.

Director and Management changes: Dr. Robert Ollar and John Chatterton have joined the Board of Directors. Dr. Ollar is cofounder of NanoLogix (as Infectech), the primary author of the majority of the company's granted patents, and returns to the company after a six year hiatus. Mr. Chatterton is former co-host of the History Channel series, Deep Sea Detectives, and is one of the world's most accomplished and well known underwater explorers. David Barnhizer has joined the company as General Counsel, bringing to the company nearly forty years of legal expertise. Detailed director and management team information can be accessed at: http://www.nanologixinc.com/index-2.html

General Counsel David Barnhizer stated: "NNLX is poised to make a significant move forward under its new board of directors and management team headed
'/>"/>

SOURCE NanoLogix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
2. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
3. NanoLogix, Inc. Makes Stock Pick List
4. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
5. NanoLogix Inc. to Present at EBW Expo & Conference 2007
6. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4